Kamada Ltd. (KMDA)

NASDAQ: KMDA · IEX Real-Time Price · USD
0.00 (0.00%)
Sep 28, 2023, 12:00 AM EDT - Market open

Company Description

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics.

It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.

It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus.

In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.

Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer.

The company markets its products through strategic partners in the United States, as well as through distributors internationally.

It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma.

Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kamada Ltd.
Kamada logo
Country Israel
Founded 1990
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 380
CEO Amir London

Contact Details

2 Holtzman St., Science Park
Rehovot, L3 7670402
Phone 97289406472
Website kamada.com

Stock Details

Ticker Symbol KMDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001567529
CUSIP Number M6240T109
ISIN Number IL0010941198
SIC Code 2834

Key Executives

Name Position
Amir London Chief Executive Officer
Chaime Orlev Chief Financial Officer
Eran Nir Chief Operating Officer
Yifat Philip Esq. Vice President of Legal, General Counsel and Corporate Secretary
David Tsur Co-Founder and Deputy Chairman
Hanni Neheman Vice President of Marketing and Sales
Ariella Raban Vice President of Human Resources
Jon R. Knight Vice President of US Commercial Operations

Latest SEC Filings

Date Type Title
Sep 14, 2023 EFFECT Notice of Effectiveness
Sep 11, 2023 F-3 Filing
Sep 7, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 30, 2023 6-K Report of foreign issuer
Aug 16, 2023 6-K Report of foreign issuer
Aug 9, 2023 6-K Report of foreign issuer
Jul 13, 2023 6-K Report of foreign issuer
Jul 12, 2023 6-K Report of foreign issuer
May 24, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 24, 2023 6-K/A Filing